Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance.

Abstract

Histone modification is associated with resistance to anti-cancer drugs. Epigenetic modifications of histones can regulate resistance to anti-cancer drugs. It has been reported that histone deacetylase 3 (HDAC3) regulates responses to anti-cancer drugs, angiogenic potential, and tumorigenic potential of cancer cells in association with cancer-associated genes (CAGE), and in particular, a cancer/testis antigen gene. In this paper, we report the roles of microRNAs that regulate the expression of HDAC3 and CAGE involved in resistance to anti-cancer drugs and associated mechanisms. In this review, roles of HDAC3-miRNAs-CAGE molecular networks in resistance to anti-cancer drugs, and the relevance of HDAC3 as a target for developing anti-cancer drugs are discussed.

• Authors: Yoojung Kwon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 20 Issue 1 (Dec 23 2018) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 30583572 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Histones
• MicroRNAs
• Histone Deacetylases
• histone deacetylase 3
• DDX53 protein, human
• DEAD-box RNA Helicases

Topics

• Antineoplastic Agents (therapeutic use)
• Cell Line, Tumor
• DEAD-box RNA Helicases (metabolism)
• Drug Resistance, Neoplasm
• Epigenesis, Genetic
• Histone Deacetylases (metabolism)
• Histones (drug effects)
• Humans
• MicroRNAs (metabolism)
• Neoplasms (drug therapy, enzymology)
• Neovascularization, Pathologic (drug therapy, enzymology)